Exenatide

Where it came from. In the early 1990s John Eng found a peptide in the venom of the Gila monster that behaved like GLP-1 but lasted far longer. Exendin-4 is about 53% identical to human GLP-1 and is a full agonist at its receptor; crucially it has glycine at position 2 instead of alanine, which makes it invisible to DPP-4, the enzyme that destroys human GLP-1 in a couple of minutes [1][6]. Synthetic exendin-4 became exenatide, the first incretin drug, approved in 2005 [2].

Diabetes. The DURATION programme established the weekly form: in 1379 patients with a baseline HbA1c of 8.4%, 24-30 weeks of exenatide 2 mg weekly significantly reduced HbA1c, fasting glucose, body weight, blood pressure and triglycerides [7]. Pooled analyses of 20 randomised trials support the same picture at high baseline HbA1c [8]. Weekly dosing is better tolerated than twice daily [9], and a separate randomised trial measured the twice-daily form's effect on BMI directly [10]. In a network comparison of ten GLP-1 agonists added to metformin, exenatide sits at the weaker end [11].

The cardiovascular trial. EXSCEL randomised 14,752 patients with type 2 diabetes. Major adverse cardiovascular events occurred in 11.4% on exenatide against 12.2% on placebo, hazard ratio 0.91, confidence interval 0.83 to 1.00 - noninferior, not superior [3]. Class-wide meta-analyses place GLP-1 agonists as a group in clearly beneficial territory [12][13], and exenatide is one of the reasons the class effect is not uniform.

Parkinson's disease. This is the most scientifically interesting part of exenatide's record and it ends in a negative result. A single-centre randomised phase 2 trial in 62 patients found that after 48 weeks of weekly exenatide, practically defined off-medication motor scores improved by 1.0 point while the placebo group worsened [4]. The finding generated a decade of interest in GLP-1 agonists as disease-modifying therapy. The phase 3 trial, a multicentre double-blind study of 215 enrolled participants over 96 weeks, found no difference; the authors concluded exenatide was safe and well tolerated but did not modify the disease [5].

Other uses. A pilot randomised trial found exenatide alongside nicotine patch improved smoking abstinence and blunted post-cessation weight gain [14], and a small case series explored it in cocaine use disorder [15]. Both are preliminary.

Exenatide activates the GLP-1 receptor, producing glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying and reduced appetite - the same mechanism as the rest of the class [1].

Its distinguishing feature is structural. Native GLP-1 is cleaved between positions 7 and 8 by DPP-4 within minutes; exendin-4 has glycine in the equivalent position, which the enzyme cannot process, so the venom peptide is intrinsically long-lived without any of the acylation tricks used in later drugs [1]. Its 39-residue sequence also carries a C-terminal extension absent from GLP-1 that contributes to receptor binding.

The rationale for the Parkinson's work was that GLP-1 receptors are expressed on neurons and that agonists have neurotrophic effects in cellular and animal models [5]. The phase 3 result does not disprove the biology; it does show that this drug at this dose does not change the course of the disease.

Two products. The immediate-release solution is injected twice daily before meals and has a half-life of about 2.4 hours. The extended-release product suspends exenatide in biodegradable poly(D,L-lactide-co-glycolide) microspheres that dissolve over a week; it takes six to seven weeks to reach steady state, and the depot causes injection-site nodules in a minority of users [7].

The tolerability difference between the two is real: continuous weekly exposure produces less nausea than intermittent twice-daily peaks [9].

Well characterised over twenty years and a 14,752-patient outcome trial. Nausea is the commonest adverse effect, more so with the twice-daily form [9]. Injection-site nodules are specific to the extended-release microspheres [7].

In EXSCEL, with a median 3.2 years of exposure, there was no excess of the safety outcomes that had been watched for across the class [3]. A systematic review of tumour risk with once-weekly GLP-1 agonists found no clear human signal [16]. Renal clearance means it is avoided in severe renal impairment [1].

In the phase 3 Parkinson's trial, serious adverse events occurred in 9% on exenatide against 11% on placebo [5] - reassuring for a two-year exposure in a frail population.

The class-wide perioperative concern about residual gastric content applies here too [17][18].

Delayed gastric emptying slows the absorption of oral drugs taken at the same time, which matters most for antibiotics and narrow-therapeutic-index medicines; the twice-daily product's label advises separating them from the injection.

With insulin or a sulfonylurea, hypoglycaemia risk rises and doses usually need reducing. Combining exenatide with another GLP-1 receptor agonist adds adverse effects without benefit.